These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 18725809)

  • 1. The Influence of a HAART regimen on the expression of HIV-associated Kaposi sarcoma.
    Paparizos VA; Kyriakis KP; Kourkounti S; Leuow K; Daskalakis E; Katsambas A
    J Acquir Immune Defic Syndr; 2008 Sep; 49(1):111. PubMed ID: 18725809
    [No Abstract]   [Full Text] [Related]  

  • 2. Relapse of Kaposi's sarcoma in HIV-infected patients switching from a protease inhibitor to a non-nucleoside reverse transcriptase inhibitor-based highly active antiretroviral therapy regimen.
    Bani-Sadr F; Fournier S; Molina JM
    AIDS; 2003 Jul; 17(10):1580-1. PubMed ID: 12824806
    [No Abstract]   [Full Text] [Related]  

  • 3. Clinical outcomes of HIV-infected patients with Kaposi's sarcoma receiving nonnucleoside reverse transcriptase inhibitor-based antiretroviral therapy in Uganda.
    Asiimwe F; Moore D; Were W; Nakityo R; Campbell J; Barasa A; Mermin J; Kaharuza F
    HIV Med; 2012 Mar; 13(3):166-71. PubMed ID: 22112164
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of PI and NNRTI HAART-based therapy on oral lesions of Brazilian HIV-infected patients.
    Ortega KL; Vale DA; Magalhães MH
    J Oral Pathol Med; 2009 Jul; 38(6):489-94. PubMed ID: 19453845
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patterns of lymphotropic herpesvirus viraemia in HIV-infected patients with Kaposi's sarcoma treated with highly active antiretroviral therapy and liposomal daunorubicin.
    Torre-Cisneros J; Pozo F; Serrano R; Vidal E; Rivero A; Tenorio A
    AIDS; 2000 Sep; 14(14):2215-7. PubMed ID: 11061671
    [No Abstract]   [Full Text] [Related]  

  • 6. HHV8 and Kaposi's sarcoma: should we really give up protease inhibitors in all HIV-infected patients?
    Philibert P; Chiche L; Caillères S; Allemand J; Rebaudet S; Delord M; Stavris C; Retornaz F; Khiri H; Halfon P
    AIDS; 2017 Sep; 31(15):2167-2169. PubMed ID: 28692546
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparison of regimens based on non-nucleoside reverse transcriptase inhibitors or protease inhibitors in preventing Kaposi's sarcoma.
    Portsmouth S; Stebbing J; Gill J; Mandalia S; Bower M; Nelson M; Bower M; Gazzard B
    AIDS; 2003 Jul; 17(11):F17-22. PubMed ID: 12853764
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Highly active anti-retroviral therapy (HAART) prolongs time to treatment failure in Kaposi's sarcoma.
    Bower M; Fox P; Fife K; Gill J; Nelson M; Gazzard B
    AIDS; 1999 Oct; 13(15):2105-11. PubMed ID: 10546864
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Changes in metabolic profile among antiretroviral-naive patients initiating protease inhibitor versus non-protease inhibitor containing HAART regimens.
    Visnegarwala F; Darcourt J; Sajja P; Menon V; Ong O; Maldonado M; White AC
    J Acquir Immune Defic Syndr; 2003 Aug; 33(5):653-5. PubMed ID: 12902814
    [No Abstract]   [Full Text] [Related]  

  • 10. Substitution for protease inhibitors in HIV therapy.
    Mikhail E
    N Engl J Med; 2003 Dec; 349(25):2460-1; author reply 2460-1. PubMed ID: 14689602
    [No Abstract]   [Full Text] [Related]  

  • 11. [Kaposi sarcoma in HIV patients: Response to antiretroviral treatment and chemotherapy].
    Lasso M; Pérez J; Noriega L; Malebrán A; Espinoza S
    Rev Med Chil; 2003 May; 131(5):483-90. PubMed ID: 12879808
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Salvage therapy for patients failing their current antiretroviral regimen.
    Albrecht MA
    AIDS Clin Rev; 2000-2001; ():139-91. PubMed ID: 10999220
    [No Abstract]   [Full Text] [Related]  

  • 13. Switch to an antiretroviral treatment of expected lower potency after effective highly active antiretroviral therapy (HAART).
    Manfredi R; Chiodo F
    J Acquir Immune Defic Syndr; 2000 Jan; 23(1):95-8. PubMed ID: 10708062
    [No Abstract]   [Full Text] [Related]  

  • 14. Initiating highly active antiretroviral therapy with newer protease inhibitors is associated with better survival compared to first-generation protease inhibitors or nevirapine.
    Crane HM; Van Rompaey SE; Kitahata MM
    AIDS Patient Care STDS; 2007 Dec; 21(12):920-9. PubMed ID: 18154489
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Considerations on the effectiveness of nevirapine in protease inhibitor-based regimen simplification.
    Martínez E; Gatell JM
    AIDS; 2007 Aug; 21(13):1829-30. PubMed ID: 17690588
    [No Abstract]   [Full Text] [Related]  

  • 16. Changing morbidity of cutaneous diseases in patients with HIV after the introduction of highly active antiretroviral therapy including a protease inhibitor.
    Calista D; Morri M; Stagno A; Boschini A
    Am J Clin Dermatol; 2002; 3(1):59-62. PubMed ID: 11817969
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changes in HIV antiretroviral prescribing practices in the United States.
    Vu QM; Shouse RL; Brady K; Brooks JT; Weiser J
    Int J STD AIDS; 2020 Jan; 31(1):22-29. PubMed ID: 31793389
    [No Abstract]   [Full Text] [Related]  

  • 18. HIV, HAART, and hyperlipidemia: balancing the effects.
    Sherer R
    J Acquir Immune Defic Syndr; 2003 Oct; 34 Suppl 2():S123-9. PubMed ID: 14703941
    [No Abstract]   [Full Text] [Related]  

  • 19. Determinants of recurrent toxicity-driven switches of highly active antiretroviral therapy. The ATHENA cohort.
    Dieleman JP; Jambroes M; Gyssens IC; Sturkenboom MC; Stricker BH; Mulder WM; de Wolf F; Weverling GJ; Lange JM; Reiss P; Brinkman K;
    AIDS; 2002 Mar; 16(5):737-45. PubMed ID: 11964530
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Superiority of protease inhibitors over nonnucleoside reverse-transcriptase inhibitors when highly active antiretroviral therapy is resumed after treatment interruption.
    Barreiro P; de Mendoza C; González-Lahoz J; Soriano V
    Clin Infect Dis; 2005 Sep; 41(6):897-900. PubMed ID: 16107992
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.